Newsroom

BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria, announced today that it has established a long-term research collaboration with the prestigious European institute, Helmholtz Centre for Infection Research (HZI) and its site Helmholtz Institute for Pharmaceutical Research Saarland (HIPS).

To combat viruses, bacteria and other pathogens, synthetic biology offers new technological approaches whose performance is being validated in experiments. Researchers from the Würzburg Helmholtz Institute for RNA-based Infection Research and the Helmholtz AI Cooperative applied data integration and artificial intelligence (AI) to develop a machine learning approach that can predict the efficacy of CRISPR technologies more accurately than before. The findings were published today in the journal Genome Biology.

Modern pharmaceutical research generates large amounts of data faster than ever before. To analyze and evaluate this data, it is collected and structured in extensive databases and thus provides the basis for the development of new active ingredients. Researchers at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) have now published two such databases. While the "ABC-HuMi" database focuses on genetic data from microorganisms that colonize humans, "ZEBRA" provides a high-resolution cell atlas of the human and mouse brain. Both databases were published in the annual database issue of the journal Nucleic Acids Research.

Despite the end of the pandemic, COVID-19 continues to pose a serious health threat. Most individuals have established robust immune protection and do not develop severe disease but the infection can still lead to marked and sometimes long-lasting disease symptoms. In the late summer of 2023 a new SARS-CoV-2 variant emerged, BA.2.86 (Pirola), which, based on genetics, differs markedly from all previously circulating variants.

From 13 to 17 November 2023, 28 young scientists gathered at BAYER in Berlin to take part in the Winter School for Translational Medical Research and Drug Development organized by ENLIGHT-TEN+ and EATRIS. Experts from science and industry provided in-depth insights into the basics of drug production and introduced the young scientists to the processes through interactive exercises and case studies. BAYER is a member of the ENLIGHT-TEN+ consortium and was primarily responsible for organizing the Winter School.

A central component of the human immune system, the NLRP3 inflammasome plays an important role in fighting off infections. However, its chronic activation is also implicated in a variety of common diseases, such as Alzheimer’s, Parkinson’s, multiple sclerosis, atherosclerosis, gout, and type II diabetes. The NLRP3 inflammasome occurs primarily in specialized immune cells in the blood and elsewhere. It is a dense complex in which several proteins interact with each other. A key protein in this complex is known by the abbreviation ASC. In non-activated immune cells, it is distributed homogeneously throughout the cell. If the NLRP3 inflammasome is activated, all of the ASC protein present in the cell aggregates in the inflammasome complex. Under an ordinary fluorescence microscope, the ASC protein, once labeled, appears as a single, bright, nearly round spot. Due to the small size and high density of this ASC speck, scientists have been unable to elucidate details of its structure inside cells. Different models were proposed in the scientific literature but a comprehensive understanding was missing.